Abstract Number: 1319 • 2017 ACR/ARHP Annual Meeting
TAS05567 Is a Novel Potent and Selective Spleen Tyrosine Kinase Inhibitor That Attenuates Disease Severity in Animal Models of Autoimmune Diseases
Background/Purpose: Spleen tyrosine kinase (Syk) is a non-receptor cytoplasmic tyrosine kinase. B-cell receptor (BCR) and Fc receptor-mediated syk signaling pathways lead to activation of several…Abstract Number: 1329 • 2017 ACR/ARHP Annual Meeting
A Quantitative Framework for Evaluating Drug Combination Treatment in Rat Collagen-Induced-Arthritis Model
Background/Purpose: Filgotinib (FIL), a JAK1 inhibitor, and GS-9876, a SYK inhibitor, are currently being evaluated as once-daily monotherapy in subjects with rheumatoid arthritis (RA). A…Abstract Number: 1454 • 2016 ACR/ARHP Annual Meeting
Combination of the SYK Inhibitor, GS-9876, with a JAK Inhibitor Increases Efficacy in a Chronic Rat Model of Collagen-Induced Arthritis
Background/Purpose: Here we demonstrate that 1) the single agent activity of GS-9876 is efficacious in a late stage rat model of collagen-induced arthritis (CIA);…Abstract Number: 1594 • 2016 ACR/ARHP Annual Meeting
First-in-Human Pharmacokinetics and Safety of Escalating Single- and Multiple-Doses of GS-9876, a Novel, Oral SYK Inhibitor, in Healthy Subjects
Background/Purpose: Spleen Tyrosine Kinase (SYK) mediates immunoreceptor signaling in a range of hematopoietic cells important for the initiation and progression of inflammatory diseases such as…Abstract Number: 2627 • 2016 ACR/ARHP Annual Meeting
The Effect of Fostamatinib with Methotrexate on Circulating Biomarkers of Synovium, Cartilage and Bone Metabolism: Potential Utility for Clinical Development Decision Making in Rheumatoid Arthriti
Background/Purpose: Fostamatinib was developed for the treatment of RA and improved signs and symptoms of RA 1, but did not improve modified Total Sharp Score…Abstract Number: 1093 • 2015 ACR/ARHP Annual Meeting
Activation of Syk-Btk Signal in Peripheral Blood B Cells in Patients with Rheumatoid Arthritis: A Potential Target for Abatacept Therapy
Background/Purpose: B cells play a pivotal role in the pathogenesis of autoimmune diseases. Although Syk function as a key molecule in BCR signaling, the pathological…Abstract Number: 2458 • 2014 ACR/ARHP Annual Meeting
Targeting IL-6, JAK or SYK? : An Analysis of Transcriptome Alteration in Peripheral Blood By RA Treatments
Background/Purpose The advances in understanding of the molecular nature of immune cell receptors enabled to offer new oral, targeted therapies. Tofacitinib (TOF) is the first…Abstract Number: 716 • 2013 ACR/ARHP Annual Meeting
The Active Metabolite Of Spleen Tyrosine Kinase Inhibitor Fostamatinib Abrogates The T Cell Priming Capacity Of Dendritic Cells
Background/Purpose: Spleen tyrosine kinase (SYK) is a core signaling protein that drives inflammatory responses and is fundamental to the propagation of signals via numerous immune-receptors…
ACR Meeting Abstracts